155 related articles for article (PubMed ID: 18680438)
1. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
Lappin G; Stevens L
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
[TBL] [Abstract][Full Text] [Related]
2. Accelerator MS: its role as a frontline bioanalytical technique.
Seymour MA
Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in biomedical applications of accelerator mass spectrometry.
Hah SS; Henderson PT; Turteltaub KW
J Biomed Sci; 2009 Jun; 16(1):54. PubMed ID: 19534792
[TBL] [Abstract][Full Text] [Related]
4. AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration.
Lappin G; Seymour M; Young G; Higton D; Hill HM
Bioanalysis; 2011 Feb; 3(4):393-405. PubMed ID: 21338259
[TBL] [Abstract][Full Text] [Related]
5. Applications of accelerator MS in pediatric drug evaluation.
Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
[TBL] [Abstract][Full Text] [Related]
6. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
[TBL] [Abstract][Full Text] [Related]
7. Adding value through accelerator mass spectrometry-enabled first in human studies.
Seymour MA
J Labelled Comp Radiopharm; 2016 Dec; 59(14):640-647. PubMed ID: 27444819
[TBL] [Abstract][Full Text] [Related]
8. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
Sarapa N; Hsyu PH; Lappin G; Garner RC
J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
[TBL] [Abstract][Full Text] [Related]
9. Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.
Spracklin DK; Chen D; Bergman AJ; Callegari E; Obach RS
CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):428-434. PubMed ID: 32562380
[TBL] [Abstract][Full Text] [Related]
10. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.
Barker J; Garner RC
Rapid Commun Mass Spectrom; 1999; 13(4):285-93. PubMed ID: 10097404
[TBL] [Abstract][Full Text] [Related]
11. The use of isotopes in the determination of absolute bioavailability of drugs in humans.
Lappin G; Rowland M; Garner RC
Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):419-27. PubMed ID: 16863443
[TBL] [Abstract][Full Text] [Related]
12. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
[TBL] [Abstract][Full Text] [Related]
13. An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration.
Lappin G; Seymour M; Young G; Higton D; Hill HM
Bioanalysis; 2011 Feb; 3(4):407-10. PubMed ID: 21338260
[TBL] [Abstract][Full Text] [Related]
14. Applications of accelerator mass spectrometry for pharmacological and toxicological research.
Brown K; Tompkins EM; White IN
Mass Spectrom Rev; 2006; 25(1):127-45. PubMed ID: 16059873
[TBL] [Abstract][Full Text] [Related]
15. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
Bae SK; Shon JH
Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
[TBL] [Abstract][Full Text] [Related]
16. The use of accelerator mass spectrometry to obtain early human ADME/PK data.
Lappin G; Garner RC
Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):23-31. PubMed ID: 16922650
[TBL] [Abstract][Full Text] [Related]
17. Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies.
Kratochwil NA; Dueker SR; Muri D; Senn C; Yoon H; Yu BY; Lee GH; Dong F; Otteneder MB
PLoS One; 2018; 13(10):e0205435. PubMed ID: 30332475
[TBL] [Abstract][Full Text] [Related]
18. Attomole detection of 3H in biological samples using accelerator mass spectrometry: application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry.
Dingley KH; Roberts ML; Velsko CA; Turteltaub KW
Chem Res Toxicol; 1998 Oct; 11(10):1217-22. PubMed ID: 9778319
[TBL] [Abstract][Full Text] [Related]
19. Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology.
White IN; Brown K
Trends Pharmacol Sci; 2004 Aug; 25(8):442-7. PubMed ID: 15276714
[TBL] [Abstract][Full Text] [Related]
20. An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808.
Kim A; Yu BY; Dueker SR; Shin KH; Kim HS; Ahn H; Cho JY; Yu KS; Jang IJ; Lee H
Clin Pharmacol Ther; 2017 Sep; 102(3):537-546. PubMed ID: 28214288
[No Abstract] [Full Text] [Related]
[Next] [New Search]
